All in all, these sources suggest a better cost/benefit ratio and, therefore, a priority use in patients with (a) LDL-C levels > 100 mg/dL before adding the PCSK-9 inhibitor [3]; (b) a recent acute myocardial infarction or multiple prior myocardial infarctions or residual multivessel coronary artery disease [69,70]; (c) clinical atherosclerosis in multiple vascular beds [72]; (d) multiple metabolic risk factors [71]. Here, PCSK9 is linked to myocardial infarction.